Transitioning to Human-Centered Science: An Off-Ramp and Transition Plan
By Paul Locke | September 4th, 2025
“For those of us who have been advocating for the development, use and adoption of human centered NAMs, the Roadmap and these announcements are a breath of fresh air. It seems that – finally – the federal government has turned the corner. But talking the talk is not enough. The transition to human centered science and away from animal testing needs an implementation plan …”
Image by FDA
From Option to Obligation: The Legal Imperative for NAMs
By Jo Anderson | August 7th, 2025
“Regulatory agencies must move from encouraging NAMs to requiring them where scientifically justified. Once merely regarded as alternatives to animal testing, NAMs have now emerged as a driving force in regulatory science.”
Image by NIH
A Bright Tomorrow for Therapeutic Orphans: The Potential for New Approach Methodologies to Bridge Data Gaps for Pregnant Patients
By Matthew Durthaler | July 24th, 2025
“As caution often precludes pregnant humans from serving as models of their own physiology, various non-human animal models have been employed. While these models have displayed some value, they are severely limited by interspecies variation and thus serve as subpar predictors of gravid human physiology.”
Sonogram captured by Matthew Durthaler, used with permission
NAMs and the Funding Frontier: How Modern Toxicology Maximizes Scientific Return on Investment
By Zachary Liebowitz | May 29th, 2025
“Funders are not only looking for scientific merit—they are also scrutinizing value and feasibility. NAMs answer all three.”
Image by ChatGPT
From Roadmap to Reality: Validating NAMs for FDA's Plan to Phase Out Animal Testing
By Yiguang Zhu | May 15th, 2025
“The FDA and the broader scientific community recognize NAMs as a means to obtain 'faster and more accurate human risk assessments' while reducing animal use.”
Image by ChatGPT
The Utility of an Intra-Agency NAM Office
By Breanne Kincaid | January 10th, 2025
“…the FDA’s NAM office represents a strategic evolution in integrating innovative methodologies into regulatory science. While it complements ICCVAM’s mission, its intra-agency focus and regulatory authority position it to drive faster, more context-specific advancements in risk assessment.“
Where Do New Approach Methodologies Belong in Toxicity Testing? Key Takeaways from ASCCT
By Breanne Kincaid | November 9, 2023
With over 350,000 discrete chemical compounds and mixtures in commerce globally – many of which have never been thoroughly assessed for their risk to human health – it is imperative that industries and regulators have access to fast, accurate, human-relevant toxicity testing methods…
The Shortage of Non-Human Primates Available for Research Opens a Door for Non-Animal Test Methods
By Sherman McFarland | September 14, 2023
Federal agencies and elected officials should not view the shortage of non-human primates (NHP) available for research as a problem that needs to be fixed by acquiring more NHPs. The real problem is what the NHP shortage allegedly does: impedes research…
Where Do MoCRA and HCA Fall in the Landscape of Animal Cosmetics Testing?
By Breanne Kincaid | August 31, 2023
From drug stores to department store cosmetic aisles, flashy labels highlighting that products are “cruelty free” or “not tested on animals” abound. It’s clear that consumer sentiment is driving substantial change in animal testing practices, and state and federal governments appear to be getting on board…
FDA Modernization Act 2.0 – An Important Step in the Right Direction, but Much Work Remains
By Rebecca Critser | August 9, 2023
In December 2022, Congress passed the FDA Modernization Act 2.0 and President Biden signed it into law as part of the Omnibus bill. This new law has implications for the future use of alternatives to animal models in science and research…